Predictive, Iterative and Adaptive Life Cycle Approaches: Managing Projects in the Knowledge Environment

In this webinar you will hear from the leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership.

Dr. James Wells moderates a panel discussion on the biggest challenges in translating organoid-based cell therapies and the steps needed to bring these technologies to market in an efficient and patient-first manner.

For more than 15 years, the costs of DNA sequencing and synthesis have been improving faster than Moore’s Law. The impacts of the improvements made to DNA sequencing are well known: whereas the original Human Genome Project cost several billion dollars, a human genome can be sequenced today for about $1,000. With DNA synthesis now available at a cost of pennies per base pair, users no longer have to undertake traditional cloning, introducing new ways of engineering biological systems.

Transporters are involved in clinically significant drug-drug interactions (DDI). Such interactions can occur at multiple sites, including in organs important in drug absorption (e.g. intestine), elimination (e.g. liver and kidneys) and distribution (e.g. brain). Notably, some of these interactions can be “hidden”, occurring in a tissue with no discernible trace in the systemic circulation. In addition, for drugs that are both transported and metabolized, DDI will most prominent when they occur at the “rate-limiting step” in the clearance of the drug.